. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: Int J Cancer. 2010 Dec 1;127(11):2588–2597. doi: 10.1002/ijc.25274

Table 1.

Primer sequences for Pyrosequencing

APC Promoter 1A	F: GGGGTTAGGGTTAGGTAGGTT R: biotin-ACTACACCAATACAACCACATATC Seq: GAGAGAAGTAGTTGTGTAAT	^*chr 5: 112,101,273-112,101,293 antisense 112,101,444-112,101,472 112,101,348-112,101,367	^** Industry source
MGMT	F: TGGTTTGGGGGTTTTTGA	chr 10, 131,154,890-131,154,907	This study
	R: biotin-CCTTTTCCTATCACAAAAATAATC	antisense 131,155,065-131,155,088
	Seq: ATTAGGAGGGGAGAGAT	131,154,921-131,154,937
RPRM	F: GGTTATTAAGGAAGTTTGGGTGTA	chr2:154,043,215-154,043,238	This study
	R: biotin-AACCCCACACCTATTCCTCC	antisense 154,043,387-154,043,406
	Seq: TTGTTTAGGGTAGGATTTAT	154,043,306-154,043,325
TWIST1	F: GTTAAGTGAGGTGGGAAGGTTGA	chr7:19,122,688-19,122,710	This study
	R: biotin-CCCACCCCCTCAACAAAAC	antisense 19,122,830-19,122,848
	Seq: GGAGAGGGGAGGAAA	19,122,721- 19,122,735

Position indicates equivalent location of primer (in unmodified sequence) in the March 2006 human reference sequence (NCBI Build 36).

^**

assay designed by QIAGEN AB, formerly Biotage AB, as published in PyroMark™ Assay Database at www.pyrosequencing.com